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Abstract
Background: HIV-1 infection dysregulates the immune system and alters gene expression in circulating monocytes.
Differential gene expression analysis of CD14
+ monocytes from subjects infected with HIV-1 revealed increased expression
of sialoadhesin (Sn, CD169, Siglec 1), a cell adhesion molecule first described in a subset of macrophages activated in
chronic inflammatory diseases.
Methodology/Principal Findings: We analyzed sialoadhesin expression on CD14
+ monocytes by flow cytometry and found
significantly higher expression in subjects with elevated viral loads compared to subjects with undetectable viral loads. In
cultured CD14
+ monocytes isolated from healthy individuals, sialoadhesin expression was induced by interferon-a and
interferon-c but not tumor necrosis factor-a. Using a stringent binding assay, sialoadhesin-expressing monocytes adsorbed
HIV-1 through interaction with the sialic acid residues on the viral envelope glycoprotein gp120. Furthermore, monocytes
expressing sialoadhesin facilitated HIV-1 trans infection of permissive cells, which occurred in the absence of monocyte self-
infection.
Conclusions/Significance: Increased sialoadhesin expression on CD14
+ monocytes occurred in response to HIV-1 infection
with maximum expression associated with high viral load. We show that interferons induce sialoadhesin in primary CD14
+
monocytes, which is consistent with an antiviral response during viremia. Our findings suggest that circulating sialoadhesin-
expressing monocytes are capable of binding HIV-1 and effectively delivering virus to target cells thereby enhancing the
distribution of HIV-1. Sialoadhesin could disseminate HIV-1 to viral reservoirs during monocyte immunosurveillance or
migration to sites of inflammation and then facilitate HIV-1 infection of permissive cells.
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Introduction
Blood monocytes constitute an important immune cell popula-
tion that is adversely impacted by HIV-1 infection. Monocytes
originate in the bone marrow from myeloid precursors [1] and are
released to circulation where their half-life in humans is about
three days [2]. During their short life span, monocytes can
differentiate to become either macrophages [3] with prolific
degradative capacity [4] or dendritic cells (DCs), which effectively
prime T cells by presenting antigens [5]. While macrophages and
DCs are readily infected by R5 HIV-1 strains, monocytes are
considered refractory to HIV-1 infection [6] with ,1% of blood
monocytes infected [7]. Even at this low rate of infection, HIV-1
appears to enter the central nervous system (CNS) via infiltrating
monocytes [8,9], which through the release of neurotoxins initiates
the neurodegenerative processes that may end in HIV-associated
dementia (HAD).
While the frequency of HAD has decreased with prevalent use
of highly active antiretroviral therapy (HAART), neurocognitive
impairment remains a reality in a substantial number of
individuals infected with HIV-1. A link between viral load and
impaired neural function is suggested by a recent study in non-
human primates indicating that monocytes may be the link
between HIV-1 in the periphery and HAD. Using an SIV-infected
macaque model, Williams et al., reported that neuronal injury was
coincident with viremia and an activated monocyte subset [10]. By
lowering the systemic viral load with antiretroviral therapy, there
was a commensurate reduction in the number of infected and
activated monocytes and a dramatic improvement in neuronal
function [10]. These observations establish a compelling link
between high viral load, activated monocytes, an increased
frequency of monocyte trafficking and a direct, negative impact
on neuronal function.
To identify cellular factors that might contribute to HIV-1
invasion of the CNS, we examined gene expression profiles of
CD14
+ monocytes from individuals infected with HIV-1. Using
high-density cDNA microarrays, we compared gene expression
profiles from subjects with high viral load (.10,000 RNA copies/
ml), subjects with low viral load (,10,000 RNA copies/ml) and
HIV-1 seronegative controls [11]. We observed a monocyte gene
expression profile related to HIV-1 infection that indicated a
‘‘hybrid’’ monocyte with increased expression of macrophage-
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CCL2), CC-chemokine receptor 5 (CCR5), and sialoadhesin (Sn,
CD169, Siglec 1) [11]. This was the first report of Sn expression in
circulating CD14
+ monocytes.
Sialoadhesin was first described as a lymphocyte cell adhesion
molecule expressed on macrophages localized in secondary
lymphoid organs [12] and later as a protein restricted to a subset
of activated macrophages related to inflammatory responses
associated with rheumatoid arthritis and atherosclerosis [13].
More recently, Sn has been implicated in diverse pathogenic
processes including rhinovirus infection [14] and porcine repro-
ductive and respiratory syndrome virus infection [15]. In HIV
infection, Sn is induced to high levels on CD14
+ monocytes shortly
after infection, possibly contributing to dysregulation of the
immune system [16]. Sialoadhesin preferably binds Neu5Ac in
a2,3 glycosidic linkage [17,18] and as the largest of the Siglecs, Sn
engages sialic acid conjugates on adjacent cells mediating cell-cell
interactions [19]. In contrast, shorter Siglecs bind sialic acid
conjugates in a cis orientation.
In this study, we report that HIV-1 infection drives monocyte
expression of Sn, which correlates with viral load in the periphery.
We identify interferons (IFN), which have been detected in the
periphery of individuals infected with HIV-1, as inducers of Sn
expression in cultured monocytes. Furthermore, using a constitu-
tive Sn-expressing cell line and IFN-stimulated primary mono-
cytes, we describe how Sn avidly binds HIV-1 and effectively
facilitates trans infection of permissive cells.
Results
Sialoadhesin expression correlates with viral load
We previously reported elevated Sn gene expression on CD14
+
monocytes from subjects infected with HIV-1 [11]. To determine
if Sn was differentially expressed on peripheral monocytes,
immunomagnetically sorted CD14
+ monocytes from HIV-1
seropositive subjects (n=24) and HIV-1 seronegative controls
(n=10) were analyzed by flow cytometry. Sialoadhesin expression,
quantified as the geometric mean, along with the subject’s viral
load (RNA copies/ml), CD4 count (cells/ml) and therapeutic
status (on or off HAART) are shown in Table 1. The range of Sn
expression on CD14
+ monocytes from subjects infected with HIV-
1 and seronegative controls is depicted in representative frequency
histogram plots (Figure 1A). To determine the relationship
between Sn expression and viral load, and CD4 count, HIV-1
seropositive subjects (n=24) were evaluated using Pearson’s
correlation analysis. Correlation of Sn expression was statistically
significant for viral load (p,0.0017) (Fig. 1B) but not with CD4
count (p,0.08) (Fig. 1C). In a follow-up study, three seropositive
subjects, initially with detectable viral loads and high Sn
expression, were subsequently retested for Sn expression after
successful HAART treatment suppressed viral replication to ,50
copies/ml. In all three cases, Sn dropped to ,200 (geometric
mean) reinforcing the link between Sn expression and viral load
(data not shown).
Interferons induce Sn expression in vitro
We wanted to know what soluble factors might drive monocyte
Sn expression in the periphery. In mice, Sn expression is
associated with inflammation in a subset of macrophages [13];
an analogous Sn response was elicited from human monocyte-
derived macrophages when treated with a combination of tumor
necrosis factor (TNF)-a and IFN-c [13]. However, in individuals
infected with HIV-1, viremia coincided with induction of type I
IFN-stimulated gene transcripts and not proinflammatory cyto-
kines [20]. We investigated if TNF-a, IFN-c or IFN-a, would
effectively induce Sn expression on CD14
+ monocytes from HIV-1
seronegative subjects. To prevent attachment activation, freshly
isolated CD14
+ monocytes were cultured in low-adherent well
plates and assayed for Sn expression by flow cytometry within
48 h. We found that Sn expression was induced by both IFN-a
and IFN-c but not TNF-a (Fig. 2). When analyzed for their effect
on THP-1 cells, a monocytic cell line, IFN-a, IFN-c and TNF-a
all induced Sn expression indicating that Sn is differentially
Table 1. Clinical data and Sn expression levels from controls
and HIV-1 seropositive subjects.
Subject Sn
a Expression Viral Load
b610
3CD4
c Therapy
d
C1 129
C2 229
C3 218
C4 72
C5 120
C6 318
C7 138
C8 194
C9 193
C10 295
V58 357 ,0.05 417 +
V60 264 ,0.05 115 +
V67 364 ,0.05 386 +
V68 251 ,0.05 201 +
V77 289 ,0.05 343 +
V91 161 ,0.05 619 +
V92 172 ,0.05 673 +
V94 129 ,0.05 211 +
V87 237 0.14 865 +
V72 197 0.50 1011 +
V69 327 1.47 354 +
V73 213 5.26 423 +
V61 375 6.35 39 -
V90 275 11.60 414 -/STI
V78 489 16.40 227 -/STI
V70 466 47.50 35 +
V59 282 73.00 294 +
V95 267 100.00 337 +
V71 401 108.00 316 -/STI
V53 467 116.00 679 -/STI
V76 565 214.00 424 -
V54 267 219.00 347 +
V75 564 750.00 12 +
V74 401 833.00 566 -
Data for controls (C, n=10), HIV-1 seropositive subjects (V, n=24)
Data sorted on increasing viral load
aSialoadhesin (Sn) expression on CD14+ monocytes by flow cytometry
quantified as the geometric mean
bHIV RNA copies/ml
cCD4 positive cells/ml
dOn (+) or off (2) highly active antiretroviral therapy; Structured treatment
interruption (STI)
doi:10.1371/journal.pone.0001967.t001
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the hypothesis that HIV-1 might directly induce Sn expression on
monocytes. When either PBMC or monocytes were treated with
5 ng/ml HIV-1NL4-3, flow cytometry analysis 48 h later did not
detect an increase in Sn expression (data not shown). While not
definitive, our data suggests that Sn expression in subjects infected
with HIV-1 is orchestrated by IFN, which is an innate immune
response to viremia.
Sn expression in a transduced THP-1 cell line
Sialoadhesin was cloned by PCR from monocyte RNA obtained
from an HIV-1 seropositive individual with a high viral load. The
cloned structural gene (5130 base pairs) was sequenced and
compared with the SIGLEC 1 in the National Center for
Biotechnology Information (NCBI) database (accession number
NM_023068). Sequence data from the cloned SIGLEC 1 consistent
with the NCBI sequence with the exception of two single
nucleotide polymorphisms (dbSNP: 6037651 and dbSNP:
709012) in the cloned gene, which generated two sense mutations
outside the sialic acid-binding domain. Neither polymorphism is
known to influence the expression or alter the function of Sn.
Subsequently, SIGLEC 1 was subcloned into an expression cassette
with a CMV promoter for constitutive expression and then
packaged into a lentiviral vector to transduce monocytic THP-1
cells. An Sn-expressing cell line, TSn, was generated by clonal
expansion of a single transductant. Analyses of the TSn cell line
showed the 190 kDa Sn protein by Western blot (Figure 3A) and
flow cytometry (Figure 3B).
Sn-dependent binding of HIV-1
Since Sn is capable of binding sialic acid conjugates on
adjoining cells, we considered the possibility that Sn would
effectively bind HIV-1 via the sialic acid residues on gp120. In
binding assays, TSn cells (1610
6 cells/ml) were incubated with
8 ng/ml HIV-1NL4-3 for 1 h at 37uC. After extensive washing to
remove nonspecifically bound virus, TSn cells were lysed and
assayed for p24 by ELISA. When compared to THP-1 controls,
TSn cells bound approximately four-fold more HIV-1NL4-3
(Fig. 4A). To characterize the TSn-HIV-1 interaction, TSn cells
were preincubated with an anti-Sn monoclonal antibody (mAb)
7D2 [13], which recognizes the V-set, N-terminal sialic acid
binding region of Sn. Preincubation with mAb 7D2 abrogated
HIV-1NL4-3 binding to TSn demonstrating that Sn is required for
HIV binding. As a control, pretreatment with a IgG1 isotype
antibody did not interfere with virus binding (Figure 4A). To
determine whether the HIV receptor CD4 was contributing to
HIV binding in this assay, THP-1 and TSn cells were
preincubated with an anti-human CD4 mAb prior to challenge
with HIV-1NL4-3. There was no change in HIV-1NL4-3 binding for
either THP-1 or TSn respectively, compared to the untreated
control (Figure 4A). With solid evidence that Sn was responsible
for HIV-1NL4-3 binding to TSn, HIV-1NL4-3 was pretreated with
sialidase to remove terminal sialic acids. Sialidase-treated HIV-
1NL4-3 resulted in significantly reduced binding to TSn cells but
had no appreciable effect on THP-1 cells (Fig. 3A). These findings
demonstrated that HIV-1NL4-3 binding to TSn is dependent on a
viral sialic acid ligand and cellular expressed Sn.
During infection, the hyper-mutation rate of HIV generates
significant genetic variation in circulating virus. To analyze
whether genetic diversity might impact virus binding, HIV-1
primary isolates from clade B and clade C were evaluated for their
ability to bind Sn. Results showed that primary isolates bound to
TSn cells in a manner similar to HIV-1NL4-3 and that binding was
Figure 1. Sn expression on CD14
+ monocytes from HIV
seropositive individuals. (A) Representative frequency histograms
of relative Sn expression on CD14
+ monocytes isolated from subjects
with high viral load (HVL, 214,000 RNA copies/ml, thick black line), low
viral load (LVL, 6,350 RNA copies/ml, thin black line) and a seronegative
control (dotted line). The isotype-matched control mAb is shown in the
shaded profile. (B) Correlation analysis of Sn expression and viral load.
Sn expression on CD14
+ monocytes from HIV seropositive subjects
(Table 1, n=24) was determined by flow cytometry and quantified as a
geometric mean for each subject. Pearson’s correlation analysis showed
statistical significance between Sn expression and the log of the
subject’s viral load (p,0.0017). (C) Correlation analysis of Sn expression
and CD4 (counts/ml) revealed no significant relationship (p,0.08).
doi:10.1371/journal.pone.0001967.g001
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pretreated with sialidase (Fig. 4A).
Next, we examined the capacity of Sn expressed on human
monocytes to bind HIV-1. Sn expression was induced by treating
CD14
+ monocytes from HIV seronegative controls with 500 U/
ml IFN-a for 48 h. IFN-a-induced monocytes incubated with
HIV-1NL4-3 bound approximately three-fold more virus compared
to non-induced monocyte controls (Fig. 4B). Preincubation with
mAb 7D2 significantly reduced HIV-1NL4-3 binding to IFN-a-
treated monocytes comparable to that observed for non-induced
monocytes, indicating that IFN-a-induced HIV-1NL4-3 binding
was due to Sn alone. When HIV-1NL4-3 was pretreated with
sialidase, subsequent binding to Sn-expressing monocytes was
impaired (Fig. 4B). Additional binding assays using primary
isolates with IFN-a-treated monocytes demonstrated that Sn
bound primary isolates with equal effectiveness. As before, virus
adsorption could be prevented to a significant extent by
pretreatments with anti-Sn mAb 7D2 or sialidase.
Sn facilitates trans infectivity
Having shown that Sn avidly binds HIV-1, we explored the
possibility that this might impact virus infectivity. To test this
theory, we employed an infectious lab-adapted HIV-1NL4-3 strain
and a reporter cell line TZM-bl, which expresses luciferase when
Figure 2. Interferon-a and -c induce Sn expression on CD14
+ monocytes and THP-1 cells. Cells were cultured in 500 U/ml IFN-a, 100 U/ml
IFN-c or 10 ng/ml TNF-a at 37uC for 48 h and analyzed for Sn expression by flow cytometry. Sn expression on IFN-a-, IFN -c- or TNF-a-treated cells
(thick black lines) and untreated cells (thin black line) were relative to an isotype-matched mAb control (shaded region). Results shown are
representative histograms from three independent experiments using monocytes from three seronegative donors.
doi:10.1371/journal.pone.0001967.g002
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infection, express the viral receptor CD4 and coreceptors CCR5
and CXCR4. When THP-1 cells were pulsed with concentrated
HIV-1NL4-3 stock for 1 h, washed extensively to remove
nonspecifically bound virus and cocultured for 48 h with adherent
TZM-bl cells, luciferase activity was slightly above background at
55 relative light units (RLU) (Fig. 5A). In contrast, TZM-bl cells
cocultivated with HIV-1NL4-3-pulsed TSn cells, expressed high
levels of luciferase (897 RLU) indicating robust trans infection by
HIV-1NL4-3. To verify that trans infection was dependent on Sn
binding of viral sialic acid conjugates, TSn was preincubated with
mAb 7D2 prior to HIV-1NL4-3 exposure. Consistent with the Sn-
HIV-1NL4-3 binding assay, pre-treatment of TSn with mAb 7D2
reduced infection in the reporter cells as illustrated by the dramatic
reduction in luciferase activity (Fig. 5A).
We then tested the potential of human CD14
+ monocytes to
facilitate trans infection of TZM-bl cells by isolating monocytes
from HIV-1 seronegative subjects and inducing Sn expression with
a 48 h pre-treatment of IFN-a. When Sn-expressing human
monocytes were pulsed with HIV-1NL4-3 and subsequently
cocultured with TZM-bl cells, luciferase activity exceeded 625
RLU indicating Sn-expressing human monocytes were capable of
facilitating trans infection (Fig. 5A). By comparison, non-induced
monocytes, which have minimal Sn expression (Fig. 2), exhibited
low luciferase activity. As a control, IFN-a treatment of TZM-bl
cells resulted in luciferase activity equal to that of background
(data not shown). These results suggest that peripheral monocytes
expressing Sn are capable of binding HIV-1 and presenting
infectious virus to susceptible cells.
It was imperative that Sn-bound HIV-1NL4-3 be the only source
of virus in these trans infection assays. We considered the possibility
that HIV-1NL4-3-infected TSn cells would provide a secondary
source of virus. To block any potential release of infectious virus
from TSn cells during the 48 h culture period, assays were
performed using indinavir (100 mM), a protease inhibitor. When
indinavir was added to the cultures, there was no decrease in
luciferase activity effectively demonstrating that TZM-bl cells were
infected by trans infection of Sn-bound HIV-1NL4-3 and not from
infected TSn cells (Fig. 5B).
The fact the Sn binds HIV-1NL4-3 and facilitates trans infection
raised the possibility that normal receptor CD4 and chemokine
coreceptor requirements might be altered by Sn-bound HIV-1NL4-
3. We tested this possibility by treating TZM-bl cells with blocking
antibodies and small molecules that prevent HIV infection by
binding to CD4 and coreceptors CXCR4 and CCR5. Pretreat-
ment of the TZM-bl cells with anti-CD4 mAb B4 [22] reduced
subsequent trans infection to background levels indicating that
CD4 remains essential for infection in this model (Fig. 5B).
Blocking coreceptor CXCR4 with either a small molecule,
AMD3100 [23] or an anti-CXCR4 mAb 12G5 [24] also
abrogated trans infection of the TZM-bl cells (Fig. 5B). Also, two
inhibitors of the CCR5 coreceptor, an anti-CCR5 mAb 2D7 [25]]
and TAK779 [26]], which should not interfere with trans infection
since HIV-1NL4-3 uses the CXCR4 coreceptor, had no effect.
From these data we conclude that Sn does not bypass receptor and
coreceptor requirements for the T-tropic (X4) HIV-1NL4-3 strain.
HIV-1 infectivity enhanced by Sn
Since individuals with detectable viral loads have circulating
cell-free HIV-1, we examined the capacity of Sn-expressing cells to
adsorb cell-free virus in conditioned medium and then trans infect
reporter cells. In a capture assay, TZM-bl cell cultures were
inoculated with HIV-1NL4-3 followed by subsequent addition of
either TSn or THP-1 cells. The baseline value for infectivity was
established with cell-free virus in the absence of any monocytic
cells. After a 48 h incubation, increasing concentrations of cell-free
virus correlated with luciferase expression and therefore infection
of TZM-bl cells (Fig. 6). Addition of THP-1 cells had minimal
impact on TZM-bl infection and was comparable to cell-free virus.
However, when TSn cells were added, infectivity of the reporter
cells increased dramatically as demonstrated by elevated luciferase
activity (Fig. 6). In fact, over the range of HIV-1NL4-3
concentrations from 800 pg/ml to 8000 pg/ml, virus infectivity
was enhanced over 5-fold in the presence of Sn compared to cell-
free virus. These data indicate that Sn captures cell-free virus and
increases the rate of infection suggesting that Sn may function as
an enhancer of HIV infection in the periphery.
Discussion
Myeloid lineage cells including monocytes, macrophages and
dendritic cells, tightly regulate Sn expression in response to specific
disease conditions. Presently, the specific factor(s) elevating Sn
during HIV-1 infection are not known. We show that Sn
expression correlates with viral loads that range from undetectable
Figure 3. Constitutive Sn expression in THP-1 by gene
transduction (TSn). (A) Immunoblot analysis of Sn protein expression.
THP-1 cell line was transduced with a plasmid encoding Sn cloned
downstream of the high-level constitutive promoter CMV. Cell lysates
were standardized, reduced with DTT and 10 mg of protein were loaded
into each well: monocytes (lane 1), IFN-a-induced monocytes (lane2),
THP-1 (lane 3) and TSn (lane 4) (M, molecular size marker). (B) Histogram
of relative distribution of Sn on the cell surface of TSn clone. TSn (thick
black line) and THP-1 cells (thin black line) were evaluated for Sn
expression by flow cytometry using anti-Sn mAb 7D2 relative to the
background isotype-matched control mAb (shaded region).
doi:10.1371/journal.pone.0001967.g003
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This finding was consistent with our previous microarray study
[11] which suggested that viral load was a determining factor in Sn
expression. This interpretation was further supported by data from
subjects whose viral loads, initially high, were suppressed to
undetectable levels following HAART treatment and exhibited a
concurrent decrease in Sn expression. In combination with our in
vitro data showing that IFN-a and IFN-c induce Sn expression in
cultured human monocytes and THP-1 cells, it is possible that
either of these cytokines drives Sn expression during HIV-1
infection. IFN-c, which is associated with immune activation, is
produced by T cells and NK cells during the acute period of
infection [27]. By comparison, IFN-a, which is present in the
serum of individuals infected with HIV-1 [28,29], is released by
plasmacytoid dendritic cells in an innate antiviral response
[30,31]. In a study by Tilton et al., monocyte production of
proinflammatory cytokines, IL-1b, IL-6 and TNF-a was dimin-
ished in HIV viremia suggesting that monocyte function was
impaired during unsuppressed viral replication [20]. Coincident
with the loss of monocyte function was an increase in Sn
expression. Importantly, this particular phenotype could be
recapitulated by stimulating monocytes with IFN-a [20]. Further
substantiating the link between Sn expression and viral load was
an observation in a treatment naı ¨ve population that Sn mRNA
expression in CD14+ monocytes dramatically increased shortly
after HIV-1 infection and continued to rise in patients who
progressed to AIDS [16]. Since high viral load is a common
feature of AIDS, elevated Sn expression would be predicted in
these patients. In aggregate, our data suggest that elevated Sn
expression on monocytes is consistent with an antiviral response,
as opposed to a restricted marker of inflammation observed in
tissue macrophages associated with rheumatoid arthritis [13].
While our findings indicate that either IFN-a or IFN-c could
induce Sn expression in peripheral monocytes, determining the
specific conditions and cytokines responsible for Sn induction will
require additional research.
Our findings present the first characterization of a monocyte
protein that adsorbs HIV-1 and facilitates trans infection. A similar
capability to bind HIV-1 and effect trans infection has been
described for other proteins including syndecan and DC-SIGN.
Syndecan, a cell surface heparan sulfate proteoglycan expressed on
macrophages, endothelial cells and fibroblasts, facilitates trans
infection of T cells and can preserve virus infectivity for an
extended period [32,33]. When expressed on macrophages,
syndecan functions as a cis-oriented HIV-1 receptor with the
virus exploiting similar attachment motifs on both syndecan and
CCR5 [34]. Trans infection has also been demonstrated in DCs,
which scavenge and internalize pathogens in tissues and then
migrate to lymph nodes where they present antigens to resting T
cells [35]. A subset of DCs express DC-SIGN (dendritic cell –
specific intercellular adhesion molecule-grabbing nonintegrin), a
type II transmembrane protein with a C-type lectin ectodomain
that can adsorb HIV-1 but does not serve as receptor for viral
fusion. Initially, DC-SIGN-dependent trans infection of permissive
cells was shown to occur in the absence of infection or even
internalization of the virus [36]. However, recent reports present
alternative pathways by which DC-SIGN may support infection of
permissive cells. DC-SIGN has been shown to rapidly internalize
intact HIV-1 into non-degradative compartments where the virus
remains competent to infect permissive cells [37]. Moreover, it has
been shown that DC-SIGN-mediated internalization is not
required for trans-enhancement but instead DC-SIGN facilitates
productive cis-infection of immature DCs and subsequent infection
of T cells [38]. Also it has been reported that DC-SIGN is not
required for DC-mediated trans infection based on observations
that neither down-regulating DC-SIGN expression nor binding of
an anti-DC-SIGN antibody adversely impacted DC-mediated trans
infection [39]. By comparison, our experiments conclusively show
that Sn-dependent trans infection is not due to productive infection
of TSn cells since trans infection assays were done in the presence
of indinavir, a potent HIV protease inhibitor. Furthermore, our
results are consistent with Sn being solely responsible for trans
infection since the anti-Sn mAb 7D2, which recognizes the Sn
sialic acid binding region, effectively abrogates trans infection of the
reporter cells.
A possible mechanism that would explain Sn-enhanced
infectivity would be that by binding both virus and target cells,
Sn effectively increases the localized virus concentration bringing
HIV-1 in close proximity to CD4 and chemokine coreceptors on
the target cell. Early characterization of Sn expressed on
Figure 4. Sn binds HIV-1 in vitro. (A) TSn binds HIV-1 in an Sn-dependant manner. TSn and THP-1 were incubated with lab-adapted HIV-1NL4-3,a n
HIV-1 clade B primary isolate or clade C primary isolate for 1 h at 37uC, washed and then assayed for HIV-1 p24 by ELISA. HIV-1 binding to Sn was
abrogated by pretreatment of cells with Sn mAb 7D2 or by pretreatment of HIV-1 with broad-spectrum sialidase. Pretreatment with IgG1 isotype
control or CD4 mAbs did not reduce binding. Data presented are the average of 3 separate experiments. (B) IFN-a-treated CD14
+ monocytes bind
HIV-1 in an Sn-dependant manner. HIV-1 binding assays were also performed on CD14
+ monocytes from seronegative controls treated with 500 U/ml
IFN-a to induce Sn expression. Pretreatment with Sn mAb 7D2 and sialidase dramatically reduced HIV-1 binding while pretreatment with IgG1 isotype
control or CD4 mAbs had little effect. Data represents monocytes from four separate donors. Error bars represent SD.
doi:10.1371/journal.pone.0001967.g004
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binds sialic acid conjugates on T cells [12], specifically CD43 [40].
Having clearly demonstrated that Sn binds HIV-1, Sn could
possibly perform dual functions, with some Sn protein capturing
free HIV-1 while other Sn molecules would engage sialic acid
conjugates on the target cell. This interaction would overcome the
electrostatic repulsive forces created by net negative charges on the
virus and the target cell surface. Repulsive forces modulate virus-
cell interactions as demonstrated by treating primary mononuclear
cells with purified sialidase, which increased susceptibility to HIV-
1 infection by reducing electrostatic repulsion [41]. The hypothesis
is that desialylation enhances the interaction of viral gp120 and
cell associated CD4/chemokine coreceptors thereby promoting
HIV-1-mediated syncytium formation. These observations suggest
that HIV-1 can exploit either condition: When sialic acid
conjugates are intact, Sn binds the virus and subsequently delivers
the virus to permissive cells. Or, if sialic acids are cleaved from
gp120 by endogenous sialidase activity, the electrostatic repulsion
is reduced permitting viral interaction with the cellular CD4/
chemokine coreceptors.
In this study, we used human monocytes and a stably
transduced cell line to demonstrate the capacity of Sn to bind
HIV-1 and facilitate the trans infection of permissive cells. While
the biological relevance of Sn expression on circulating monocytes
remains to be determined, the potential impact of enhancing viral
infectivity and possibility disseminating HIV-1 via monocyte
trafficking to the CNS are clearly important considerations.
Materials and Methods
Cells and viruses
Monocytes for in vitro experiments were isolated from HIV-1
seronegative healthy donors (Blood Centers of the Pacific, San
Francisco, CA). In brief, cells were flushed out of leuko-reduction
filters with 40 ml PBS without Ca
2+ and Mg
2+ using a syringe.
Monocytes were enriched by negative selection using RosetteSep
according to the manufacturer (StemCell Technologies, Vancou-
Figure 5. Sn-dependent trans infection of reporter cells TZM-bl.
(A) Sn-expressing cells, TSn and IFN-a-induced monocytes, bind HIV-1
and infect TZM-bl cells in trans. Cells were incubated with HIV-1NL4-3 for
1 h, washed and then cocultured with TZM-bl cells for 48 h. HIV-1
infection of TZM-bl was defined by luciferase expression and quantified
as relative light units (RLU). Cells pretreated with Sn mAb 7D2 showed
significantly reduced capacity to facilitate trans infection of TZM-bl cells
while mAb IgG1 isotype control had no effect. (B) HIV-1 receptor
inhibitors block trans infection. Receptor and coreceptor requirements
for trans infection of TZM-bl cells were tested by incubating TZM-bl
cells with receptor inhibitors including mAbs to CD4, CXCR4 or CCR5,
and small molecules AMD3100 or TAK779 prior to adding TSn with
bound HIV-1NL4-3. The CD4, CXCR4, CCR5, AMD3100 and TAK779
receptor inhibitors were tested individually with TZM-bl and did not
induce luciferase expression (data not shown). As a control, productive
infection of TSn cells was prevented by addition of indinavir (100 mM).
Data presented are the average of three separate experiments. Error
bars represent SD.
doi:10.1371/journal.pone.0001967.g005
Figure 6. Sn-expressing cells capture HIV-1NL4-3 and enhance
infectivity. TZM-bl cell cultures were seeded with various concentra-
tions of HIV-1NL4-3 (800–8000 pg/ml). Monocytic cells, TSn or THP-1
cells, were added and cocultured for 48 h. The capacity of Sn to capture
HIV-1NL4-3 in the cell culture medium and trans infect TZM-bl cells was
analyzed for TSn, THP-1 and cell-free virus. Luciferase expression in HIV-
1NL4-3-infected TZM-bl cells was quantified as relative light units (RLU).
Results were compiled from 3 separate experiments. Error bars
represent SD.
doi:10.1371/journal.pone.0001967.g006
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obtained from the Cell Culture Facility (UCSF, San Francisco, CA)
and cultured in RPMI-1640 supplemented with 10% FBS, 1.0 mg/
ml gentamicin and 2 mM L-glutamine at 37uCi n5 %C O 2 .L a b -
adapted HIV-1NL4-3 was a generous gift from Dr. Joe Wong.
Primaryisolates92US660(HIV-1B1)andMW/93/959(HIV-1C2)
and reporter cell line TZM-bl were obtained from NIH AIDS
Research and Reference Reagent Program (Germantown, MD).
Lab-adapted HIV-1NL4-3 and primary isolates HIV-1 B1 and C2
werereplicatedinPBMCfrom3seronegativedonors(BloodCenters
of the Pacific) using a standard in vitro HIV-1 replication protocol
(SRA Life Sciences; available on the NIH AIDS Research and
Reference Reagent Program website). TZM-bl cells were also
obtained from the NIH AIDS Research and Reference Reagent
Program and cultured in DMEM H-21 supplemented with 10%
FBS and 1.0 mg/ml gentamicin at 37uCi n5 %C O 2 .
Quantification of in vivo Sn expression by flow cytometry
This study received IRB approval from the University of
California, San Francisco and the Veterans Affairs Medical
Center, San Francisco and written consent was obtained from
participating subjects. For flow cytometric analysis, CD14
+
monocytes were isolated within 2 h from fresh blood obtained
from donors recruited at the San Francisco VA Medical Center. In
brief, 30 ml of blood was collected in BD Vacutainer CPT tubes
(BD, Franklin Lakes, NJ) and centrifuged to enrich for PBMC.
Monocytes were isolated from PBMC by positive immunomag-
netic cell sorting using CD14 Microbeads (Miltenyi Biotec,
Auburn, CA) which yielded .90% purity when assayed by flow
cytometry (FACSCalibur; BD Biosciences, San Jose, CA) using
anti-CD14-FITC (BD Pharmingen, San Diego, CA). Sn expres-
sion was quantified by flow cytometry using anti-human Sn
monoclonal antibody (mAb) 7D2 (Novus Biologicals, Littleton,
CO) and secondary PE anti-mouse IgG1 (BD Pharmingen).
Mouse IgG1 (BD Pharmingen) was used as a non-specific control
antibody. The geometric mean of the channel value for 10
4 cells
was determined using CellQuest software (BD Biosciences).
In vitro induction of Sn
THP-1 cells or CD14
+ monocytes from HIV-1 seronegative
controls (1610
6 cells) were stimulated with 500 U/ml IFN-a2a
(PBL Biomedical Laboratories, Piscataway, NJ), 100 U/ml IFN-c
or 10 ng/ml TNF-a (R&D Systems, Minneapolis, MN) in RPMI-
1640 supplemented with 10% FBS, 1.0 mg/ml gentamicin and
2 mM L-glutamine at 37uCi n5 %C O 2 for 48 h in Costar Ultra
Low Attachment plates (Corning, Lowell, MA) with rotation to
prevent adherence.
SN cloning and constitutive expression in clone TSn
Total RNA was extracted from CD14
+ monocytes isolated from
an HIV-1 seropositive individual using RNeasy Mini kit (Qiagen,
Valencia, CA). cDNA was generated using Superscript III First-
strand cDNA Synthesis kit (Invitrogen, Carlsbad, CA). SN was
cloned by RT-PCR (94uC for 2 min followed by 35 cycles of 94uC
for 30 sec, 58uC for 1 min, 72uC for 6 min with extension at 72uC
for 10 min) using FailSafe PCR PreMix Selection Kit (Epicentre
Biotechnologies, Madison, WI). Primers were as follows: forward
59- TGA TAT CTT AAG GCA CAA GAA CCT GCT ATG G -
39 and reverse 59- AGA TAT CTA GAC AAC ACC ACT GGT
CAG CC -39. The PCR product was inserted into pCR2.1 and
sequenced (Cleveland Genomics, Cleveland, OH). SN was cloned
into pENTR1A then subcloned into pLenti6/V5-Dest using
GatewayH technology and then packaged into the lentiviral vector
using ViraPower Lentiviral Expression System in a 293FT cell line
(all from Invitrogen). Lentiviral suspensions (3 ml) were combined
with THP-1 cells (1610
7) and mixed with polybrene (8 mg/ml).
Lentivirus was loaded onto THP-1 cells by spinoculation (6006g
for 1.5 h). After, cells were resuspended in RPMI-1640 supple-
mented with 10% FBS, 1.0 mg/ml gentamicin and 2 mM L-
glutamine and cultured at 37uCi n5 %C O 2. Clonal selection was
done in the presence of 5 mg/ml blasticidin.
Immunoblot
THP-1, TSn, monocytes and monocytes stimulated with 500 U/
ml IFN-a2a (2610
6) were washed with PBS and lysed with ice-cold
lysis buffer containing 10 mM HEPES pH 7.9, 10 mM KCl,
0 . 1m ME D T A ,0 . 1m ME G T A ,0 . 5m MP M S F ,1m MD T Ta n d
0.5% NP-40. Cell lysates were normalized by protein concentration,
reduced with DTT and 10 mg of sample protein were loaded into a
4–12% Bis-Tris gel (Invitrogen). Proteins were fractionated in
reducing conditions by electrophoresis for 1 h at 200 V, electro-
blotted for 1 h at 100 V onto a polyvinylidene difluoride (PVDF)
membrane (GE Healthcare, Picastaway, NJ). The PVDF membrane
was probed with Sn mAb 7D2 (1:1000; Novus Biologicals) and
secondary peroxidase-labeled horse anti-mouse IgG (1:5000; Vector
Laboratories, Burlingame, CA) then visualized with ECL plus on a
Typhoon Scanner (GE Healthcare, Picastaway, NJ).
In vitro HIV binding assays
Cellular binding of lab-adapted HIV-1NL4-3 and primary
isolates clade B (HIV-1 92US660) and clade C (MW/93/959)
was assessed using THP-1, TSn, monocytes and IFN-a2a-
stimulated monocytes. In brief, 2.5610
5 cells/250 ml PBS were
pulsed with 2 ng p24-normalized virus stocks for 1 h at 37uC.
Cells were vigorously washed 5 times with PBS by vortexing and
centrifugation at 3006g. To demonstrate that increased binding of
HIV-1 to TSn and monocytes stimulated with IFN-a2a involved
Sn, cells were pretreated with 0.5 mg Sn mAb 7D2, mAb IgG1
isotype control (Novus) or CD4 mAb RPA-T4 (BD Bioscience) for
1 h at 37uC. Sialic acid residues on HIV-1 were removed with
4610
24 U/ml sialidase from Clostridium perfringens (Roche, In-
dianapolis, IN) for 1 h at 37uC. HIV-1 bound to cells was
quantified by HIV p24 ELISA (Zeptometrix, Buffalo, NY).
Trans infection assay
TZM-bl cells were distributed into 96-well plates (5610
3 cells/
well) and cultured in RPMI-1640 supplemented with 10% FBS,
1.0 mg/ml gentamicin for 48 h at 37uCi n5 %C O 2. On the same
day, CD14
+ monocytes from controls were isolated and half were
stimulated with 500 U/ml IFN-a2a for 48 h at 37uCi n5 %C O 2
with rotation to prevent adherence to plastic. After, THP-1, TSn,
monocytes and monocytes stimulated with IFN-a2a (1610
6 cells/
250 ml PBS) were pulsed with 2 ng HIV-1NL4-3 for 1 h at 37uC,
washed vigorously 5 times with PBS by vortexing and centrifu-
gation at 3006g, then resuspended in 1 ml RPMI-1640+10%
FBS. To demonstrate involvement of Sn, cells were pretreated
with 0.5 mg Sn mAb 7D2 or mAb IgG1 isotype control for 1 h at
37uC and washed 3 times with PBS. To confirm which coreceptors
were required for trans infection via TSn, TZM-bl cells were
pretreated with 0.5 mg/ml anti-CD4 RPA-T4 (BD Bioscience),
0.5 mg/ml anti-CXCR4 12G5 or anti-CCR5 2D7, or 10 mM
AMD3100 or TAK779 (all from NIH AIDS Research and
Reference Reagent Program). After, the TZM-bl media was
replaced with 100 ml of the cell suspension (1610
5 cells) and
cultured for 48 h at 37uCi n5 %C O 2. Productive infection of TSn
and TZM-bl cells was prevented by the presence of 100 mM
indinavir protease inhibitor (NIH AIDS Research and Reference
Reagent Program). Infection of the TZM-bl cells was quantified as
CD169 Enhances HIV Infectivity
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the Bright-Glo
TM detection system (Promega, Madison, WI) and a
SpectraMax M5 microplate reader (Molecular Devices, Sunny-
vale, CA).
Enhancement of HIV-1NL4-3 infectivity
The ability of Sn-expressing cells to capture HIV-1NL4-3 in
solution and then infect TZM-bl cell in trans was compared to cell-
free virus. TZM-bl cells (5610
3 cells/well) were distributed into
96-well plates and incubated for 48 h at 37uCi n5 %C O 2. After,
the media was replaced with 50 ml of dilutions of HIV-1NL4-3 and
50 mlo f2 610
5 THP-1 or TSn cells. The plate was rotated at
1000 rpm for 1 min and incubated for 48 h at 37uC. Luciferase
activity was measured using the Bright-Glo
TM(Promega) and a
SpectraMax M5 microplate reader (Molecular Devices).
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